Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Arthritis Rheumatol. 2022 Sep 29;74(11):1746–1754. doi: 10.1002/art.42262

Figure 3.

Figure 3.

Radiographic progression by anti-PAD4 IgG1 status. A and B, Crude and adjusted frequency of any increase in SHS (A). Frequency was adjusted for gender, anti-PAD2 positivity, average IL-6, baseline pain and baseline SHS >0. Frequency of radiographic progression of SHS ≥ 4 units/year (B). Frequency was adjusted for average IL-6. C, Frequency of any radiographic progression according to anti-PAD4 IgG1 and anti-CCP and/or RF status. The OR and 95% CI are shown. OR were adjusted for gender, anti-PAD2, average IL-6, baseline pain, and baseline SHS >0. D, Frequency of any radiographic progression according to anti-PAD4 IgG1 status and baseline SHS. Disease duration, anti-PAD3/4 antibodies, HLA-DRB1, DAS-28, Swollen joint count, HAQ score, and rheumatoid nodules were not significant in multivariate analyses. Average CRP was not co-modelled with average IL-6 because they are collinear.